Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wondering whether Hims & Hers Health at US$26.33 still offers value, or if the best entry points are already behind you? This article focuses squarely on what the current price may imply. The stock has been volatile, with a 7 day return of a 5.7% decline, a 30 day return of 37.6%, a year to date return of a 21.2% decline, and a 1 year return of a 46.8% decline, set against a 3 year return that is very large and a 5 year return of 166.0%. Recent coverage has highlighted how Hims & Hers Health...
Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.
HIMS broadens its DTC platform with GLP-1 access, a new Benefits hub and global expansion to broaden convenient, personalized care.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $29.76 as of April 21st. HIMS’s trailing and forward […]
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Investing.com -- Abortion access in the United States was dealt a legal blow on Friday after a Federal Appeals Court issued a temporary stay halting the distribution of Mifepristone by mail.
Two class action lawsuits claim Hims & Hers Health did not adequately safeguard sensitive customer data during recent data breaches. The suits allege delayed notification to affected customers and increased risk of identity theft, and they seek damages plus stronger data security oversight. These cases introduce fresh legal and reputational questions for NYSE:HIMS that have not been widely covered so far. For investors watching NYSE:HIMS, this legal development adds a new angle to a stock...
Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4% in the afternoon session after the stock's momentum weakened as Amazon.com entered the weight management market through its One Medical platform.
Hims & Hers Health (NYSE:HIMS) has nominated Kofi Amoo-Gottfried as a new independent director to its board. Amoo-Gottfried brings senior marketing experience from roles at DoorDash and Meta. The company is also reducing the overall size of its board as part of this change. Hims & Hers Health operates in telehealth and wellness, with a model built around digital customer acquisition, recurring subscriptions and branded experiences. As virtual care, online pharmacies and direct to consumer...
A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patients with lung and pancreatic cancer. Investors quickly drew parallels to daraxonrasib, the high-profile lead asset from Revolution Medicines Daraxonrasib has been on the receiving end of a storm of media coverage following an endorsement from former Nebraska Sen. Ben Sasse.
OMCL vs. HIMS: Which Stock Is the Better Value Option?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.